{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-25-000105","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.108146+00:00","generated_at":"2026-05-17T23:46:58.140967+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"GeneDx Q2 revenue $102.7M (+49% YoY); raises FY outlook to $400-415M","bullets":["Exome/genome test revenue $85.9M (+69% YoY) on volume of 23,102 results (+28%).","Adjusted net income $15.0M vs. loss of $2.0M a year ago; GAAP net income $10.8M.","Adjusted gross margin expanded to 71% from 62% in Q2 2024.","Acquired Fabric Genomics for $33.2M in cash, net of cash acquired.","AAP now recommends exome/genome as first-line test for children with global developmental delay."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-25-000105","json":"https://secwatch.observer/filing/0001818331-25-000105.json","markdown":"https://secwatch.observer/filing/0001818331-25-000105.md","text":"https://secwatch.observer/filing/0001818331-25-000105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833125000105/0001818331-25-000105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833125000105/wgs-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:46:58.140967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}